Idogen Overview

  • Founded
  • 2008

  • Status
  • Public

  • Employees
  • 10

  • Stock Symbol

Stock Symbol
  • Share Price
  • $0.04

  • (As of Friday Closing)

Idogen General Information


Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • Medicon Village
  • Scheelevagen 2
  • 223 81 Lund
  • Sweden
+46 046-275 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Idogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.04 $0.04 $0.02 - $0.35 $3.17M 72.5M 910K -$0.17

Idogen Financials Summary

In Thousands,
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 3,100 921 3,535 749
Revenue 0 0 0 0
EBITDA (4,259) (4,359) (2,765) (2,833)
Net Income (4,421) (4,524) (2,909) (3,457)
Total Assets 4,970 2,549 6,198 3,336
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Idogen Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Idogen‘s full profile, request access.

Request a free trial

Idogen Patents

Idogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210299069-A1 Psammaplin a for modulating ido expression Pending 26-Aug-2016 0000000000
EP-3503896-A1 Psammaplin a for modulating ido expression Withdrawn 26-Aug-2016 0000000000
EP-3504326-A1 Novel use Withdrawn 26-Aug-2016 0000000000
US-20190192543-A1 Novel use Abandoned 26-Aug-2016 0000000000
US-20190201431-A1 Ex vivo methods of inducing ido expression in antigen presenting cells using a compound selected from the group consisting of azacytidine, and decitabine Abandoned 26-Aug-2016 A61K31/7068
To view Idogen’s complete patent history, request access »

Idogen Executive Team (14)

Name Title Board Seat Contact Info
Dennis Henriksen Ph.D Chief Technology Officer
Åsa Schiött Ph.D Chief Scientific Officer
Neil Thomas Ph.D Chief Business Officer
Rory Graham Chief Regulatory Officer
Vicki Venizelos Chief Regulatory Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Idogen Board Members (2)

Name Representing Role Since
0000 0000000 Self Co-Founder, Advisor & Board Member 000 0000
000000 Ø000 Ventac Partners Board Member 000 0000
To view Idogen’s complete board members history, request access »

Idogen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Idogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Idogen‘s full profile, request access.

Request a free trial